Antiviral drugs : Potent agents, promising therapies for COVID‑19 and therapeutic limitations
© 2022. The Author(s), under exclusive licence to Springer Medizin Verlag GmbH, ein Teil von Springer Nature..
Antiviral drugs inhibit viral replication by interaction with specific elements of the viral replication cycle. Directly acting antiviral agents have revolutionized the therapeutic options for chronic infections with human immunodeficiency virus (HIV), hepatitis B virus (HBV) and hepatitis C virus (HCV). Pharmacological developments constantly improve therapeutic and prophylactic options for diseases caused by herpes viruses, which is of particular relevance for immunocompromised patients. While infections with persistent viruses, such as HIV, HBV or herpes viruses principally so far cannot be cured, complete elimination of viruses that cause acute infections is possible; however, acute infections, such as influenza or coronavirus disease 2019 (COVID-19) offer only a small therapeutic window for antiviral strategies due to their pathophysiological dynamics. The optimal time point for antiviral agents is immediately after exposure to the virus, which frequently limits its application in practice. An effective pre-exposure or postexposure prophylaxis has been established for infections with HIV and influenza A/B and also gains relevance for infections with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:63 |
|---|---|
| Enthalten in: |
Der Internist - 63(2022), 1 vom: 01. Jan., Seite 118-128 |
| Sprache: |
Deutsch |
|---|
| Weiterer Titel: |
Antivirale Medikamente : Potente Wirkstoffe, Hoffnungsträger bei COVID‑19 und therapeutische Grenzen |
|---|
| Beteiligte Personen: |
Malin, Jakob J [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antiviral Agents |
|---|
| Anmerkungen: |
Date Completed 18.01.2022 Date Revised 02.11.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s00108-021-01233-4 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM335239714 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM335239714 | ||
| 003 | DE-627 | ||
| 005 | 20231225225405.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||ger c | ||
| 024 | 7 | |a 10.1007/s00108-021-01233-4 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1117.xml |
| 035 | |a (DE-627)NLM335239714 | ||
| 035 | |a (NLM)34988607 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a ger | ||
| 100 | 1 | |a Malin, Jakob J |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Antiviral drugs |b Potent agents, promising therapies for COVID‑19 and therapeutic limitations |
| 246 | 3 | 3 | |a Antivirale Medikamente : Potente Wirkstoffe, Hoffnungsträger bei COVID‑19 und therapeutische Grenzen |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 18.01.2022 | ||
| 500 | |a Date Revised 02.11.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2022. The Author(s), under exclusive licence to Springer Medizin Verlag GmbH, ein Teil von Springer Nature. | ||
| 520 | |a Antiviral drugs inhibit viral replication by interaction with specific elements of the viral replication cycle. Directly acting antiviral agents have revolutionized the therapeutic options for chronic infections with human immunodeficiency virus (HIV), hepatitis B virus (HBV) and hepatitis C virus (HCV). Pharmacological developments constantly improve therapeutic and prophylactic options for diseases caused by herpes viruses, which is of particular relevance for immunocompromised patients. While infections with persistent viruses, such as HIV, HBV or herpes viruses principally so far cannot be cured, complete elimination of viruses that cause acute infections is possible; however, acute infections, such as influenza or coronavirus disease 2019 (COVID-19) offer only a small therapeutic window for antiviral strategies due to their pathophysiological dynamics. The optimal time point for antiviral agents is immediately after exposure to the virus, which frequently limits its application in practice. An effective pre-exposure or postexposure prophylaxis has been established for infections with HIV and influenza A/B and also gains relevance for infections with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Post-exposure prophylaxis | |
| 650 | 4 | |a Viral infections | |
| 650 | 4 | |a Virus replication | |
| 650 | 4 | |a Virustatics | |
| 650 | 7 | |a Antiviral Agents |2 NLM | |
| 700 | 1 | |a Bunse, Till |e verfasserin |4 aut | |
| 700 | 1 | |a Spinner, Christoph D |e verfasserin |4 aut | |
| 700 | 1 | |a Protzer, Ulrike |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Der Internist |d 1960 |g 63(2022), 1 vom: 01. Jan., Seite 118-128 |w (DE-627)NLM000030767 |x 1432-1289 |7 nnns |
| 773 | 1 | 8 | |g volume:63 |g year:2022 |g number:1 |g day:01 |g month:01 |g pages:118-128 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s00108-021-01233-4 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 63 |j 2022 |e 1 |b 01 |c 01 |h 118-128 | ||